
    
      This is an open-label, non-randomised, single-dose study to evaluate the safety,
      tolerability, pharmacokinetics and pharmacodynamics of MT-1303 in subjects with inflammatory
      bowel disease (Crohn's Disease and Ulcerative Colitis).
    
  